Oil Prices Surge Amid Syrian Turmoil

by THEFUTURE.TEAM

December 9, 2024

Oil prices kicked off the week on an upward trajectory after rebels ousted the 43-year rule of President Bashar al-Assad and his father, Hafez al-Assad. The prospect of civil war has fueled concerns over heightened tensions in the Middle East, raising the risk of supply chain disruptions.

Key Figures

Brent crude rose 0.52% to $71.49 per barrel.
US light crude climbed 0.58% to $67.59 per barrel.

These movements followed the seizure of Damascus by Hayat Tahrir al-Sham, a radical rebel group, on Sunday. This marked the end of 50 years of Assad family rule, raising fears of a possible escalation into civil war.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The oil market’s upward trend comes after two consecutive weeks of losses for both Brent and US light crude, driven by growing expectations of oversupply in 2025.

Market Constraints

Despite the rise in prices, broader market sentiment remains weighed down by weak demand in China, the world’s second-largest economy. This prompted Saudi Aramco, the world’s top crude exporter, to slash its January 2025 prices for the Asian market to the lowest level since early 2021.

OPEC+ Strategy Shift

In a move that surprised markets, OPEC+ postponed its planned production increase for January by an entire year, rather than the previously expected three months. OPEC+ controls about 50% of global oil production, and the group had initially planned to ramp up production from October 2024. However, slowing demand, especially from China, along with rising output from other producers, forced multiple delays to the increase.

With the global energy market still under pressure from weak demand, the cartel’s decision signals a shift toward a more cautious production strategy to maintain price stability.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Breaking news